ArriVent BioPharma priced its upsized NASDAQ IPO at $18 per share, raising $175M. Click here for more on biotech deals, financing, trials and approvals. ( read original story ...)
Balance of loans in Shanghai up 7.3 pct at end of December 2023
Specifically, the balance of loans in Chinese yuan stood at 10.59 trillion yuan, up 8.6 percent year on year, according to the People's Bank of China Shanghai Head Office. Outstanding foreign currency ... ( read original story ...)
China stocks steady after cut to bank reserves
SHANGHAI, Jan 25 (Reuters) - China stocks opened steady on Thursday after the country's central bank announced a deep cut to bank reserves the previous day to support a fragile economy and tumbling ... ( read original story ...)
Why Investors Should Not Rush Into China’s Stock Market
Investors should be wary of the government's efforts to prop up China's equity markets. The weakness in the property market could be the tip of an iceberg. ( read original story ...)
Wilting fortunes: Wong Kar-wai’s Blossoms Shanghai drama series offers stock investors painful reality check on past glory
Today, not much resembles the reels in Blossoms Shanghai. China’s legion of 200 million retail investors can be forgiven for hankering for that gravity-defying bygone era of the 1990s. ( read original story ...)
ArriVent’s Nasdaq Debut Nabs $175M as Signs Indicate an Opening IPO Window
ArriVent BioPharma will apply the IPO cash toward furmonertinib, which the biotech says could offer advantages over Takeda Pharmaceutical and Johnson & Johnson drugs that address the same lung cancer ... ( read original story ...)
Stock market today: Asian shares mostly rise, led by gains in Chinese markets following policy moves
Asian shares were mostly higher on Thursday, with Chinese stocks extending gains after Beijing announced a raft of policies to support sagging markets. Hong Kong rose 1.8% and Shanghai surged 3%. Benchmarks inched higher in Tokyo and Seoul. ( read original story ...)